Supreme Court sides with Hikma in ‘skinny label’ casenews2026-06-04T15:04:41+00:00June 4th, 2026|Endpoints News|
ADC Therapeutics’ confirmatory data for Zynlonta muddied by death ratesnews2026-06-04T11:01:18+00:00June 4th, 2026|Endpoints News|
Bristol Myers turns focus to AI costs after broad rollout to workersnews2026-06-03T17:58:20+00:00June 3rd, 2026|Endpoints News|
Axsome pushes back generic entry for narcolepsy drug until 2040news2026-06-03T17:37:25+00:00June 3rd, 2026|Endpoints News|
Regeneron doubles down on CytomX after other pharmas walked awaynews2026-06-03T14:56:16+00:00June 3rd, 2026|Endpoints News|
Lilly gives hospitals deadline to comply with 340B claims data policynews2026-06-02T17:50:25+00:00June 2nd, 2026|Endpoints News|
Travere pays Everest $112M upfront to grow rare kidney disease pipelinenews2026-06-02T13:55:55+00:00June 2nd, 2026|Endpoints News|
Citing ‘dangerous deals,’ lawmakers propose China restrictionsnews2026-06-02T12:00:58+00:00June 2nd, 2026|Endpoints News|
Servier signs $1.55B upfront deal for Edgewise’s muscular dystrophy assetsnews2026-06-01T12:31:49+00:00June 1st, 2026|Endpoints News|
#ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remainnews2026-06-01T10:19:50+00:00June 1st, 2026|Endpoints News|
